Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON FORTE versus MOLINDONE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON FORTE versus MOLINDONE HYDROCHLORIDE.
ETRAFON-FORTE vs MOLINDONE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETRAFON-FORTE is a combination of perphenazine (a phenothiazine antipsychotic) and amitriptyline (a tricyclic antidepressant). Perphenazine blocks postsynaptic dopamine D2 receptors in the mesolimbic system. Amitriptyline inhibits reuptake of serotonin and norepinephrine, enhancing neurotransmission. Additionally, amitriptyline blocks histamine H1, muscarinic, and alpha-adrenergic receptors.
Dopamine D2 receptor antagonist; also blocks serotonin 5-HT2A receptors and alpha-adrenergic receptors.
ETRAFON-FORTE (perphenazine 4 mg / amitriptyline 25 mg) oral tablets: 1 tablet three times daily or 1 tablet four times daily. Maximum daily dose: 4 tablets (perphenazine 16 mg / amitriptyline 100 mg).
50-225 mg/day orally in 3-4 divided doses; usual effective dose 50-75 mg/day; maximum 225 mg/day.
None Documented
None Documented
Terminal elimination half-life of perphenazine: 8-12 hours; amitriptyline: 13-36 hours (mean ~20 hours). Steady-state achieved in 3-7 days. Clinical context: twice-daily dosing maintains therapeutic levels.
1.5-2 hours; shorter than typical antipsychotics, requiring multiple daily dosing.
Primarily renal (approximately 70-80% as metabolites, <5% unchanged). Biliary/fecal elimination accounts for about 15-20% due to enterohepatic recirculation of metabolites.
Renal: 65-70% as metabolites and unchanged drug; Fecal: 20-25%; Biliary: minor.
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic